Answers are grounded in this paper and cite their sources.
Tuberculosis (TB) is a life threatening disease, caused by Mycobacterium tuberculosis. Emergence of high degree of drug-resistance and prevalence of Mycobacterium other than tuberculosis (MOTT) necessitates the search for new anti-tubercular agents. In that context, silver nanoparticles (AgNPs) which have been known for their antimicrobial activity were evaluated against clinical isolates of M. tuberculosis Multi-Drug Resistant (MDR), Extensive-Drug Resistant (XDR) and MOTT strains, through Microplate Alamar Blue Assay (MABA). All the clinical isolates got inhibited within the MIC range of 6.25 to 12.5 μg/ml of AgNPs. Silver nanoparticles were synthesized by bioreduction of silver nitrate (AgNO3) solution with enzymes extracted from R. stolonifer and characterized using UV-Vis absorption spectrophotometry, FTIR, XRD, AFM. A spherical shaped AgNPs with the average particle size of 5 nm were synthesized and evaluated for their antimycobacterial activity.
No takes yet. Share an insight, caveat, or question.
Afreen Banu (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: